aiwiki.page
English
Science / Biology / serum-albumin

Serum Albumin

Serum albumin is the principal protein of blood plasma, maintaining colloid osmotic pressure and transporting numerous endogenous substances and drugs.

36 keywords1 linked from7 not yet writtenWritten by AI
ProteinAmino AcidDisulfide BondAlpha HelixHydrophobic Effe…Hydrogen BondpHGeneSerum Albu…

Serum albumin is a soluble protein that constitutes approximately 50–60% of the protein in normal human blood plasma. Produced predominantly by the liver, it circulates at a typical adult concentration of about 35–50 g/L and also occupies a substantial pool outside the bloodstream. Its principal physiological roles are maintaining plasma colloid osmotic pressure and binding a wide range of substances, including fatty acids, bilirubin, hormones, metal ions, and medicines.

Despite its name, serum albumin is present in both plasma and serum: plasma is the fluid component of anticoagulated blood, whereas serum remains after blood has clotted. Albumin is not consumed in clot formation. In clinical medicine, its concentration provides information about several interacting processes—protein synthesis, inflammation, vascular permeability, fluid balance, and protein loss—rather than serving as a specific measure of any one disease or of nutritional status.

Human serum albumin is among the most extensively studied circulating proteins. Its molecular structure explains its unusually versatile binding properties, while its synthesis, distribution, and recycling explain its relatively long persistence in the body. Albumin is also manufactured as a therapeutic product, used widely as a laboratory reagent, and exploited as a carrier in drug development.

Molecular structure and the albumin family

Mature human serum albumin is a single polypeptide of 585 amino-acid residues, with a molecular mass of approximately 66.5 kDa. Its sequence contains 35 cysteine residues: 34 participate in 17 intramolecular disulfide bonds, while one, cysteine 34, normally retains a free sulfhydryl group. These covalent cross-links stabilize the molecule without making it rigid. Albumin can change conformation as ligands bind or as its chemical environment changes.

The protein consists of three homologous domains, designated I, II, and III, each divided into A and B subdomains. Its secondary structure is predominantly alpha-helical, with little conventional beta-sheet structure. The repeated domain arrangement reflects ancient duplication within the albumin gene family. Human serum albumin is related to alpha-fetoprotein, vitamin D–binding protein, and afamin, but these proteins have different binding preferences and physiological roles. The shared family relationship does not make them functionally interchangeable.

Albumin has a broadly heart-shaped structure with internal cavities and surface pockets that accommodate chemically diverse molecules. Hydrophobic regions bind nonpolar groups, while charged and polar residues provide more specific contacts. The hydrophobic effect, hydrogen bonding, and electrostatic interactions all contribute to binding. This combination allows one protein to transport many substances without requiring a unique transporter for each one. It also means that occupancy of one site can affect the shape or affinity of another.

At physiological pH, albumin carries a substantial net negative charge; its isoelectric point is approximately 4.7. Numerous acidic side chains contribute to its solubility and interactions with positively charged molecules and ions. Changes in pH produce recognizable conformational transitions. Strong acidification expands the molecule, whereas more modest changes alter domain relationships and ligand affinity. Such behavior is important in experimental studies, although extreme laboratory conditions should not be equated directly with normal circulation.

Human albumin is not normally an enzymatically glycosylated protein. It can, however, undergo nonenzymatic glycation when sugars react with accessible amino groups. Other modifications include oxidation, truncation, and formation of mixed disulfides at cysteine 34. Consequently, circulating albumin is a population of related molecular forms rather than a completely uniform substance. Bovine serum albumin, a common laboratory reagent, resembles the human protein in overall architecture but differs in sequence and binding behavior; experimental findings obtained with one species’ albumin do not automatically apply quantitatively to another.

Gene expression, synthesis, distribution, and turnover

Human albumin is encoded by the gene ALB, located on chromosome 4 at region 4q13.3. The primary translation product contains 609 amino-acid residues. Removal of an 18-residue signal peptide and a six-residue propeptide produces the mature 585-residue protein. The signal sequence directs the developing polypeptide into the endoplasmic reticulum, where folding and disulfide-bond formation take place before subsequent processing and secretion.

In healthy adults, the liver commonly produces approximately 10–15 g of albumin per day, although production varies with body size and physiological state. Synthesis is regulated at several levels, including gene expression, availability of amino acids, hormonal signals, and the functional state of hepatocytes. During systemic inflammation, cytokine-mediated changes in hepatic protein production favor some acute-phase proteins while albumin synthesis may decline. Albumin is therefore classified as a negative acute-phase protein, although reduced production alone does not explain every rapid fall in its blood concentration.

Only about 40% of the exchangeable albumin pool is normally inside blood vessels; much of the remainder occupies interstitial fluid. Albumin continuously crosses the microvascular barrier and returns through the lymphatic system. Its measured plasma concentration therefore depends not just on synthesis and degradation but also on exchange between compartments and on plasma volume. Intravenous fluid administration, dehydration, burns, or increased vascular permeability can change the concentration without a corresponding proportional change in total body albumin.

Albumin has a circulating half-life of approximately 19–21 days in healthy adults. Its persistence depends partly on the neonatal Fc receptor, usually abbreviated FcRn. Cells internalize extracellular proteins into acidic endosomes. Albumin binding to FcRn under these acidic conditions allows a portion of the internalized protein to escape degradation and return to the cell surface, where the higher extracellular pH promotes release. FcRn also recycles immunoglobulin G, although albumin and immunoglobulin bind to different receptor sites.

Albumin not rescued from intracellular degradation is broken down in lysosomes, and its amino acids re-enter metabolic pools. The kidney also participates in albumin handling: the glomerular filtration barrier restricts passage, while proximal tubular cells retrieve much of the albumin that reaches the filtrate, notably through the receptors megalin and cubilin. Disease can alter filtration, retrieval, degradation, or several of these processes together. These interacting pathways explain why albumin kinetics cannot be inferred reliably from a single blood measurement.

Colloid osmotic pressure and fluid exchange

Albumin is the largest contributor to plasma oncotic pressure, also called colloid osmotic pressure. This is the component of osmotic pressure associated with macromolecules that are relatively restricted by a biological barrier. Albumin is particularly influential because it combines high concentration with a lower molecular mass than many other abundant plasma proteins. At a given mass concentration, a smaller protein supplies more individual molecules and therefore a larger ideal osmotic contribution.

For a dilute ideal solution, the osmotic-pressure relationship is

π=cRT,\pi = cRT,

where π\pi is osmotic pressure, cc is the molar concentration of solute particles, RR is the gas constant, and TT is absolute temperature. Albumin solutions in plasma are not perfectly ideal. Interactions among proteins and the distribution of diffusible ions around charged macromolecules modify the relationship. Normal total plasma colloid osmotic pressure is approximately 25 mmHg, with albumin commonly accounting for roughly three-quarters of it.

Fluid movement across microvessels is often described by a Starling-type expression:

Jv=LpS[(Pc−Pi)−σ(πc−πi)].J_v = L_pS\left[(P_c-P_i)-\sigma(\pi_c-\pi_i)\right].

Here, JvJ_v is fluid flow, LpSL_pS represents hydraulic conductance multiplied by surface area, Pc−PiP_c-P_i is the hydrostatic pressure difference, and σ\sigma describes how effectively the barrier restricts protein passage. The oncotic terms represent the opposing osmotic contribution. This equation connects protein concentration to filtration, but its interpretation depends critically on the actual barrier and on where the relevant protein concentrations are measured.

The revised Starling framework emphasizes the endothelial glycocalyx, a carbohydrate-rich layer at the inner surface of blood vessels. In many continuous capillary beds, the effective oncotic gradient acts across this layer, between plasma and the relatively protein-poor space immediately beneath it. It is not simply the difference between plasma and bulk interstitial fluid. Under steady conditions, many tissues exhibit continuing low-level filtration with lymphatic return rather than sustained venous-end reabsorption of the kind shown in older simplified diagrams.

A low albumin concentration can favor edema, but edema is not determined by albumin alone. Capillary hydrostatic pressure, endothelial permeability, renal sodium retention, and lymphatic drainage also matter. In inflammatory states, albumin can escape into tissues more rapidly, reducing its effectiveness in retaining fluid within the circulation. This distinction is central to interpreting both disease and treatment: increasing blood albumin concentration does not necessarily repair the vascular barrier or reverse the processes causing tissue swelling.

Transport, binding, and chemical protection

Albumin transports poorly water-soluble substances through an aqueous circulation. Long-chain fatty acids occupy several binding sites, allowing their movement between adipose tissue, liver, muscle, and other organs. Binding is reversible, and occupancy changes with fasting, feeding, exercise, and metabolic state. Albumin-bound fatty acids form a circulating reservoir in equilibrium with a much smaller unbound fraction. That unbound fraction is especially important for exchange with cell membranes and uptake into tissues.

Unconjugated bilirubin, produced during heme breakdown, also binds strongly to albumin. This binding permits transport to the liver and restricts the concentration of freely diffusible bilirubin. In newborns, insufficient binding capacity or displacement by other substances can contribute to increased exposure of tissues to unbound bilirubin. Albumin additionally carries portions of circulating thyroid hormones and steroid hormones, although more specialized proteins bind many of these hormones more tightly. Its high abundance compensates, in part, for its generally lower binding affinity.

Two extensively studied drug-binding regions are known as Sudlow sites I and II, identified through the work of Gillian Sudlow and colleagues in the 1970s. Site I lies mainly in subdomain IIA and binds compounds such as warfarin; site II lies mainly in subdomain IIIA and binds compounds such as diazepam and ibuprofen. These are useful organizing categories rather than rigid compartments. Drugs may occupy secondary sites, and fatty acids can alter drug binding through competition or conformational effects.

For a simplified single-site interaction between albumin AA and a ligand LL,

A+L⇌AL,Kd=[A][L][AL].A+L \rightleftharpoons AL, \qquad K_d=\frac{[A][L]}{[AL]}.

The dissociation constant KdK_d expresses binding affinity under specified conditions. Real plasma binding may involve several sites, competing ligands, and changing pH. For many medicines, the unbound fraction is the fraction directly available for membrane passage, target binding, and clearance. A rise in that fraction does not necessarily produce a sustained rise in unbound concentration, because distribution and elimination can change simultaneously. Consequently, protein-binding displacement alone is not a sufficient explanation for a clinically important drug interaction.

Albumin also binds calcium, zinc, copper, and other ions at sites with differing selectivity. Roughly 40% of circulating calcium is protein-bound, predominantly to albumin, so total calcium can decrease when albumin decreases even if biologically active ionized calcium remains unchanged. Cysteine 34 contributes substantially to the pool of free thiol groups in plasma and participates in reactions with oxidants and electrophiles. Binding of heme and redox-active metals can also influence their chemical reactivity. These protective activities are real but context-dependent: oxidation or other modifications may change albumin’s binding properties rather than simply turning a single antioxidant function on or off.

Altered concentrations and inherited variants

Low serum albumin, or hypoalbuminemia, results from several distinct mechanisms: reduced synthesis, increased loss, redistribution outside blood vessels, accelerated turnover, or dilution. These mechanisms often coexist. In advanced chronic liver disease, reduced functioning hepatocyte mass can limit synthesis. In severe inflammation or critical illness, increased microvascular escape and changes in distribution can reduce the measured concentration rapidly, on a timescale too short to be explained by the protein’s normal half-life alone.

Renal albumin loss is prominent in nephrotic syndrome, where abnormalities of the glomerular filtration barrier allow excessive protein passage into urine. Gastrointestinal loss occurs in protein-losing enteropathy, which can arise from several intestinal or lymphatic disorders. Large burns and extensive exudative skin disease can also produce substantial losses. Conversely, an elevated blood albumin concentration most often reflects reduced plasma water, as in dehydration or sample-related hemoconcentration, rather than a major increase in albumin production.

Serum albumin is associated with disease severity and outcomes in many clinical populations, but this does not make it a specific causal factor or a direct measure of dietary protein intake. Malnutrition can contribute to low albumin, particularly when prolonged or accompanied by disease, yet inflammation and fluid balance frequently dominate the laboratory result. Albumin concentration alone therefore cannot distinguish inadequate nutrient intake from altered distribution or increased loss. Its relatively slow turnover further limits its ability to represent short-term changes in intake.

Inherited ALB variants illustrate the difference between albumin quantity and albumin function. Congenital analbuminemia is a rare, usually autosomal recessive condition in which circulating albumin is extremely low or nearly absent. Affected individuals may have edema, altered lipid concentrations, and changes in drug binding, but some survive into adulthood with fewer manifestations than might be expected from albumin’s normal abundance. Increases in other circulating proteins and additional physiological adaptations provide partial compensation, not complete functional replacement.

Other variants alter electrophoretic mobility or ligand affinity without greatly reducing the amount of protein. Bisalbuminemia describes the presence of two distinguishable albumin forms, often seen as a split band during electrophoresis. Familial dysalbuminemic hyperthyroxinemia results from albumin variants with increased affinity for thyroid hormone, especially thyroxine. It can produce elevated total thyroid hormone measurements and method-dependent abnormalities in some free-hormone assays despite normal thyroid physiology. These variants show why an unexpected laboratory pattern may reflect altered binding or assay behavior rather than disease of the organ usually associated with the measured substance.

Laboratory measurement and diagnostic interpretation

Routine serum albumin assays commonly use dye-binding chemistry. Bromocresol green and bromocresol purple change their optical properties when bound to albumin under controlled conditions, allowing concentration to be estimated by spectrophotometry. These methods are rapid and inexpensive, but their selectivity differs. Bromocresol green can bind some non-albumin proteins and produce positive bias, particularly in certain low-albumin or inflammatory samples. Bromocresol purple can also show method- and sample-dependent bias, including in some patients with renal disease.

Immunochemical methods use antibodies directed against albumin and are particularly important for low concentrations, such as those measured in urine. Serum protein electrophoresis separates albumin from major globulin fractions and helps reveal unusual band patterns. Mass spectrometry can characterize variants, fragments, glycation, and oxidative modifications, although such detailed molecular analysis is not part of most routine albumin testing. Assay results therefore reflect both biological properties and the analytical procedure used.

A typical adult serum reference interval is about 35–50 g/L, equivalent to 3.5–5.0 g/dL, but intervals vary with laboratory method, age, and population. Posture and prolonged venous stasis during blood collection can increase measured concentration through local hemoconcentration. Fluid administration can lower it through dilution. Because these effects do not necessarily represent changes in synthesis or total body protein, serial results are most interpretable when analytical method and sampling conditions are considered together.

Urinary albumin is a separate measurement with particular importance in kidney disease. The urine albumin-to-creatinine ratio partly adjusts for variation in urine concentration. Common categories are less than 30 mg/g creatinine, 30–300 mg/g, and greater than 300 mg/g, often designated A1, A2, and A3. The intermediate category was historically called “microalbuminuria,” but the albumin molecules are not unusually small; the term referred to the quantity excreted. Exercise, fever, infection, and other transient conditions can influence urinary albumin, so persistence is a distinct diagnostic consideration.

Albumin also affects interpretation of other laboratory results. Low albumin reduces the usual anion gap because albumin is a major unmeasured anion. It changes total calcium and the total concentrations of many protein-bound drugs and hormones. Formulas that “correct” total calcium for albumin are approximations and can perform poorly in critical illness or substantial acid–base disturbance. Glycated albumin provides a biomarker of glycemic exposure over a shorter interval than glycated hemoglobin, generally around two to three weeks, but its interpretation is affected by disorders that change albumin turnover. No single albumin-related test captures concentration, binding capacity, structural integrity, and turnover simultaneously.

Therapeutic preparations and clinical evidence

Therapeutic human albumin is produced principally by fractionating donated plasma, followed by purification, stabilization, and pathogen-reduction procedures. Preparations commonly contain approximately 4–5% albumin or 20–25% albumin. The lower-concentration products are roughly iso-oncotic with plasma, whereas the concentrated products are hyperoncotic. These percentages describe protein concentration, not a universal difference in clinical effectiveness. Their physiological effects depend on administered volume, vascular permeability, kidney function, and the patient’s underlying condition.

Albumin infusion can expand plasma volume, but the extent and duration of expansion vary. When the endothelial barrier is relatively intact, infused albumin is retained more effectively within the circulation. When permeability is increased, part of the dose leaves the vascular compartment. Albumin is therefore not simply a fixed-volume “sponge” that draws a predictable amount of fluid into blood vessels in every setting. Recognized risks include circulatory overload and uncommon hypersensitivity reactions, and manufacturing controls address the infectious risks associated with plasma-derived products.

The 2004 SAFE trial compared 4% albumin with saline for fluid resuscitation in nearly 7,000 intensive-care patients. Overall 28-day mortality was similar between the groups. A subsequent analysis of participants with traumatic brain injury found higher mortality among those assigned albumin, demonstrating that an overall trial result cannot be applied indiscriminately to every subgroup. The 2014 ALBIOS trial, involving more than 1,800 patients with severe sepsis, compared crystalloid treatment with a strategy that also used 20% albumin to maintain a target serum concentration. It did not show a significant overall mortality benefit at 28 or 90 days.

Albumin has more specifically defined uses in complications of cirrhosis. These include prevention of circulatory dysfunction after large-volume paracentesis and use alongside other treatment in selected patients with spontaneous bacterial peritonitis or hepatorenal syndrome. A landmark 1999 trial in spontaneous bacterial peritonitis found that adding albumin to antibiotic treatment reduced renal impairment and mortality in the studied population. These findings concern particular clinical syndromes and treatment protocols, not the correction of every low albumin result.

Trials of longer-term administration in cirrhosis have examined a different question from acute volume resuscitation. The 2018 ANSWER trial reported improved outcomes with scheduled albumin in a selected outpatient population with cirrhosis and ascites. By contrast, the 2021 ATTIRE trial in hospitalized patients with decompensated cirrhosis found no benefit on its primary composite outcome from targeting a higher albumin concentration and recorded more serious adverse events in the intervention group. Differences in patient selection, dosing, treatment duration, and clinical setting are essential to interpreting these results. Albumin concentration is thus both a physiological variable and a treatment target whose usefulness must be established separately for each indication.

Research history, laboratory uses, and engineered carriers

The name albumin derives from the Latin albumen, meaning egg white, and historically referred to a broad class of water-soluble proteins. Serum albumin is distinct from ovalbumin, the major protein of egg white, despite the shared terminology. Early protein chemistry separated blood proteins according to solubility, precipitation, and later electrophoretic behavior. These methods established albumin as the major soluble protein fraction of serum before its sequence and three-dimensional structure were known.

A major practical advance came from Edwin J. Cohn and colleagues, who developed controlled cold-ethanol fractionation of plasma during the 1940s. Manipulating ethanol concentration, pH, ionic strength, and temperature allowed separation of plasma protein fractions, including albumin. This work supported the production of stable plasma-derived preparations during World War II and helped establish industrial plasma fractionation. Later purification methods added more selective chromatographic steps and improved control over contaminants and product consistency.

Sequence studies and structural analysis subsequently connected albumin’s clinical behavior with its molecular architecture. The mature human sequence was established in the 1970s. In 1992, Xiao-Min He and Daniel C. Carter reported a three-dimensional structure of human serum albumin determined by X-ray crystallography, providing a framework for interpreting its repeated domains and ligand-binding cavities. Structures with fatty acids, drugs, and other ligands have since revealed that albumin is conformationally adaptable rather than merely a passive container with permanently fixed pockets.

Bovine serum albumin is widely used to stabilize enzymes, reduce loss of dilute proteins onto vessel surfaces, and block nonspecific binding in immunoassays. It is a common reagent in immunohistochemistry, biochemical assays, and cell-culture systems. “Fraction V” is a traditional commercial designation derived from fractionation history, not a guarantee of identical composition across products. Fatty-acid content, aggregates, trace contaminants, and processing conditions can differ. Albumin used as a carrier or blocking reagent can itself bind the substance under investigation, making reagent grade and preparation relevant experimental variables.

Albumin is also a platform for extending drug exposure. Covalent attachment of a fatty-acid-containing group can promote reversible albumin binding, while genetic fusion can join a therapeutic protein directly to albumin. Both approaches can reduce rapid renal clearance and exploit albumin recycling, although the outcome depends on the construct’s binding, stability, and biological activity. Other products use albumin-containing particles; albumin-bound paclitaxel is an established example in cancer treatment. These formulations employ different mechanisms and should not be treated as one interchangeable delivery technology.

Recombinant production offers alternatives to donor-plasma sourcing and permits deliberate sequence modification. Research also examines albumin adducts as records of exposure to reactive chemicals, its oxidation state as an indicator of systemic chemical stress, and engineered variants with altered ligand or receptor affinity. A persistent experimental challenge is that structural changes can affect several properties at once: increasing affinity for a carrier receptor or drug may also alter release, tissue distribution, or degradation. Demonstrating improved binding in an isolated assay is therefore distinct from demonstrating useful behavior in a living organism.